This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Is Eli Lilly's Stock in a Bubble?
by Tracey Ryniec
Shares of Eli Lilly are up 150% over the last 2 years as investors are bullish about the new weight loss drugs. Is it too hot to handle?
NVONegative Net Change LLYNegative Net Change
pharmaceuticals stock-performance
PCE/Core PCE Inflation In Line With Estimates in June
by Zacks Equity Research
PCE/Core PCE Inflation In Line With Estimates in June.
BMYPositive Net Change MMMPositive Net Change TROWNegative Net Change CLPositive Net Change
consumer-staples finance multi-sector-conglomerates pharmaceuticals
Pre-Markets Swell, PCE Behaves, Several Q2 Beats
by Mark Vickery
Pre-market futures are jumping this morning, though this may have to do with favorable market conditions after the sell-off mid-week.
BMYPositive Net Change MMMPositive Net Change TROWNegative Net Change CLPositive Net Change
ad-tech consumer-discretionary consumer-staples earnings finance industrial-products pharmaceuticals
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
SNYNegative Net Change AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change ABBVPositive Net Change
pharmaceuticals
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
BMYPositive Net Change PFEPositive Net Change CORTPositive Net Change TRDANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pe-ratio pharmaceuticals
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs earnings-preview medical messenger-rna pharmaceuticals vaccines
Company News for Jul 26, 2024
by Zacks Equity Research
Companies In The News Are: ABBV, VLO, NOC, LUV.
NOCPositive Net Change LUVNegative Net Change VLOPositive Net Change ABBVPositive Net Change
aerospace airlines oil-energy pharmaceuticals
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
ANIPPositive Net Change VKTXPositive Net Change RAPTPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
by Kinjel Shah
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
JNJPositive Net Change MRNAPositive Net Change KVUEPositive Net Change
pharmaceuticals
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
by Zacks Equity Research
Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.
REGNPositive Net Change SNYNegative Net Change AZNPositive Net Change TEVAPositive Net Change
earnings pharmaceuticals
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
by Zacks Equity Research
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
REGNPositive Net Change RHHBYPositive Net Change BAYRYNo Net Change
earnings medical pharmaceuticals
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
by Zacks Equity Research
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
REGNPositive Net Change RHHBYPositive Net Change BAYRYNo Net Change
earnings medical pharmaceuticals
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
by Ekta Bagri
Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.
BIIBNegative Net Change BMRNNegative Net Change AGENPositive Net Change SAGEPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
by Zacks Equity Research
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
SNYNegative Net Change AZNPositive Net Change MRKNegative Net Change AMGNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline
by Zacks Equity Research
Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.
RHHBYPositive Net Change PFEPositive Net Change LLYNegative Net Change
pharmaceuticals
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
GSKPositive Net Change JNJPositive Net Change HLNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen
BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
pharmaceuticals
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
by Zacks Equity Research
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
AMGNPositive Net Change AGENPositive Net Change ADVMNegative Net Change GPCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.
REGNPositive Net Change SNYNegative Net Change AMGNPositive Net Change SNDXNegative Net Change
biotechs medical pharmaceuticals
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
by Ekta Bagri
Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.
BMYPositive Net Change PFEPositive Net Change TSVTPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
AZNPositive Net Change MRKNegative Net Change ELANPositive Net Change
pharmaceuticals
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
SNYNegative Net Change AZNPositive Net Change BMYPositive Net Change ABBVPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.
GERNPositive Net Change AMGNPositive Net Change AGENPositive Net Change ADVMNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals